For the 2025 outlook, sales growth is now expected to be 8-14% at CER, and operating profit growth is now expected to be 10-16% at CER. Sales and operating profit growth reported in Danish kroner is now expected to be 3 and 5 percentage points lower than at CER, respectively. The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025, reflecting the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition. The outlook is related to lower growth expectations for Wegovy in the US obesity market, for Ozempic in the US GLP-1 diabetes market as well as for Wegovy in select IO markets. Novo Nordisk (NVO) continues the global rollout of Wegovy to more markets and invests in commercial activities towards driving market penetration for both Wegovy and Ozempic.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk reports 1H EPS DKK 12.49 vs. DKK 10.17 last year
- Novo Nordisk Reports Strong H1 2025 Growth but Lowers Full-Year Outlook
- Novo Nordisk Shares Down 44% YTD as Wegovy Sales Jump 67%, But Guidance Stays Lower
- Novo Nordisk downgraded to Neutral from Buy at UBS
- Novo Nordisk Faces Legal Storm Over Misleading Projections